Patents by Inventor Randall Owens

Randall Owens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11464768
    Abstract: Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing NPI-NH score in a human with Alzheimer's Disease comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing agitated behavior or aggressive behavior in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 11, 2022
    Assignee: ACADIA Pharmaceuticals Inc.
    Inventors: Bruce Duane Coate, James Randall Owen, Mark Donald Knowles, Srdjan R. Stankovic, James M. Youakim
  • Publication number: 20220016101
    Abstract: The disclosure provides, in part, a method of treating anxious distress with major depressive disorder in a patient in need thereof, comprising administering to the patient N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N?-(4-(2-methylpropyloxy)phenylmethyl)carbamide or a pharmaceutically acceptable salt thereof. Also provided herein is a method of treating depression in a patient in need thereof, wherein the patient is also suffering from Parkinson's disease, comprising orally administering to the patient 34 mg of N-(4-fluorophenylmethyl)-N-1-methylpiperidin-4-yl)-N?-(4-(2-methylpropyloxy)phenylmethyl)carbamide once daily, as well as methods for the treatment of a SSRI or SNRI-induced sexual dysfunction in a human subject.
    Type: Application
    Filed: October 30, 2019
    Publication date: January 20, 2022
    Applicant: ACADIA Pharmaceuticals Inc.
    Inventors: Ethan S. Burstein, Srdjan R. Stankovic, Bryan Dirks, Maurizio Fava, James Randall Owen, Daryl DeKarske
  • Publication number: 20200237739
    Abstract: Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing NPI-NH score in a human with Alzheimer's Disease comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing agitated behavior or aggressive behavior in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 14, 2017
    Publication date: July 30, 2020
    Inventors: Bruce Duane Coate, James Randall Owen, Mark Donald Knowles, Srdjan R. Stankovic, James M. Youakim
  • Publication number: 20110269203
    Abstract: The present invention to provides a method for the conversion of biomass comprising cellulosic or carbohydrate polymers, into lipids useful for the production of biofuels. The method is achieved by providing the biomass to a culture of lipogenic zooplankton in a contained space, whereby the zooplankton consume the biomass, thereby converting the biomass to zooplankton derived biomass with increased lipid content. The zooplankton derived biomass is collected, lipids are extracted, and the lipids are converted to fuel through methods known in the art.
    Type: Application
    Filed: April 29, 2010
    Publication date: November 3, 2011
    Inventor: Randall Owen Sigle
  • Patent number: 6723558
    Abstract: Polyenv vaccines are provided that comprise mixtures of at least 4 to about 10,000 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv vaccines and viruses, including the use of the polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or treatment of HIV infection. The viral vaccines of the invention are optimally combined with a recombinant HIV env booster, or a recombinant HIV env gene DNA priming or boosting vaccine.
    Type: Grant
    Filed: May 10, 2000
    Date of Patent: April 20, 2004
    Assignee: St. Jude Children's Research Hospital
    Inventors: Julia Hurwitz, Christopher Coleclough, Randall Owens, Karen Slobod